30 Participants NeededMy employer runs this trial

Implementation Intervention for Alcoholism and Alcoholic Liver Disease

LH
Overseen ByLamia Haque, MD MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Yale University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

Who Is on the Research Team?

LH

Lamia Haque

Principal Investigator

Yale University

Are You a Good Fit for This Trial?

Inclusion Criteria

* Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Hepatology clinicians participate in educational sessions and implementation facilitation intervention

12 months
2 educational sessions (in-person or virtual)

Follow-up

Participants are monitored for the feasibility and acceptability of the intervention

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • Implementation Intervention

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Hepatology CliniciansExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborator

Trials
865
Recruited
1,091,000+